Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement

Sep

01

Today In Oncology

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country

Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

Real-World Incidence and Management of Infusion-Related Reactions to Monoclonal Antibody Therapy

Advertisement

© 2025 HSP News Service, L.L.C.